HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 173 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Speaking a thousand words – how a cancer image collection is... September 8, 2021 Partnership in a pandemic: how Credit Suisse delivered an incredible Charity... May 19, 2021 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... August 6, 2025 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Zanubrutinib Colposcopia: Cómo prepararse y qué saber How I’m Working to Erase the Stigma of Lung Cancer: A... April is Occupational Therapy (OT) Month- What is OT and how...
